CHMP4C: A Potential Drug Target and Biomarker for Cancer (G92421)

Target Name: CHMP4C

NCBI ID: G92421

CHMP4C

CHMP4C: A Potential Drug Target and Biomarker for Cancer

CHMP4C, also known as Shax3, is a protein that is expressed in various tissues throughout the body. It is a key regulator of the cell cycle, which plays a crucial role in the development and progression of cancer. CHMP4C has also been identified as a potential drug target and a biomarker for various diseases, including cancer.

The cell cycle is the process by which a cell grows, replicates its DNA, and performs necessary cell functions. The cell cycle is regulated by a complex network of proteins, including CHMP4C. CHMP4C is a key regulator of the G1 phase of the cell cycle , which is the phase when the cell prepares for cell division.

During the G1 phase, CHMP4C helps to ensure that the cell has enough copies of its DNA and histamines, such as histone modifications, to begin the cell division process. It also helps to regulate the levels of spindle tubulin, which are important for the proper structure and function of the microtubules that move the chromosomes during cell division.

In addition to its role in regulating the cell cycle, CHMP4C has also been shown to play a role in the development and progression of cancer. It has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together and form tissues.

CHMP4C has also been shown to be involved in the regulation of cell migration, which is the process by which cells move from one location to another in the body. It has been shown to play a role in the migration of cancer cells to new sites of growth.

As a potential drug target, CHMP4C has been shown to have a variety of potential therapeutic benefits. For example, it has been shown to have anti-tumor effects in cell culture models of various types of cancer, including breast, lung, and ovarian cancer . It has also been shown to have the potential to inhibit the growth of cancer cells in animal models of cancer.

In addition to its potential therapeutic benefits, CHMP4C has also been identified as a potential biomarker for various diseases, including cancer. Its expression has been shown to be elevated in a variety of cancer types, including breast, lung, and ovarian cancer.

One of the challenges in studying CHMP4C as a potential drug target is its relatively small size. While it is a key regulator of the cell cycle and has been shown to play a role in the development and progression of cancer, it is not yet clear exactly how it fits into the complex network of proteins that regulate the cell cycle.

In addition, CHMP4C is also a complex protein, and its function in cell cycle regulation and cancer development may be dependent on its interactions with other proteins. Further research is needed to fully understand its role in these processes.

Overall, CHMP4C is a protein that has the potential to be a drug target or biomarker for various diseases, including cancer. Further research is needed to fully understand its role in cell cycle regulation and its potential therapeutic benefits.

Protein Name: Charged Multivesicular Body Protein 4C

Functions: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: upon phosphorylation by AURKB, together with ZFYVE19/ANCHR, retains abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. Deactivation of AURKB results in dephosphorylation of CHMP4C followed by its dissociation from ANCHR and VPS4 and subsequent abscission (PubMed:22422861, PubMed:24814515). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release. CHMP4A/B/C are required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413)

The "CHMP4C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHMP4C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets